Targeting AKR1B10 by drug repurposing with epalrestat overcomes chemoresistance in non-small cell lung cancer patient-derived tumor organoids.
Kanve Nagaraj SuvileshManjunath YariswamyYulia I NussbaumMohamed GadelkarimMurugesan RajuAkhil SrivastavaGuangfu LiWesley C WarrenChi-Ren ShyuFeng GaoMatthew A CiorbaJonathan B MitchemSatyanarayana RachaganiJussuf T KaifiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
PDTOs are efficient preclinical models recapitulating the tumor characteristics and are suitable for drug testing. AKR1B10 can be targeted by repurposing epalrestat to overcome chemoresistance in NSCLC. Epalrestat has the potential to advance to clinical trials in drug-resistant NSCLC patients due to favorable toxicity, pharmacological profile, and bioavailability.
Keyphrases
- drug resistant
- small cell lung cancer
- clinical trial
- multidrug resistant
- end stage renal disease
- acinetobacter baumannii
- ejection fraction
- chronic kidney disease
- advanced non small cell lung cancer
- newly diagnosed
- prognostic factors
- oxidative stress
- peritoneal dialysis
- adverse drug
- pseudomonas aeruginosa
- mesenchymal stem cells
- brain metastases
- drug delivery
- bone marrow
- open label
- climate change
- study protocol
- cancer stem cells
- human health
- patient reported